^
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
olaparib Sensitive: A1 - Approval
Cancer Discov - 1 week
|
olaparib Sensitive: A1 - Approval
Cancer Discov - 1 week
|
BRCA2 mutation
|
Ovarian Cancer
|
BRCA2 mutation
|
Ovarian Cancer
|
olaparib Sensitive: A1 - Approval
Cancer Discov - 1 week
|
olaparib Sensitive: A1 - Approval
Cancer Discov - 1 week
|
miR-142 overexpression
|
Ovarian Cancer
|
miR-142 overexpression
|
Ovarian Cancer
|
bevacizumab Sensitive: C3 – Early Trials
J Ovarian Res - 1 week
|
bevacizumab Sensitive: C3 – Early Trials
J Ovarian Res - 1 week
|
miR-25 underexpression
|
Ovarian Cancer
|
miR-25 underexpression
|
Ovarian Cancer
|
bevacizumab Sensitive: C3 – Early Trials
J Ovarian Res - 1 week
|
bevacizumab Sensitive: C3 – Early Trials
J Ovarian Res - 1 week
|
TP53 mutation
|
Ovarian Cancer
|
TP53 mutation
|
Ovarian Cancer
|
modafinil Sensitive: C3 – Early Trials
Cancer Gene Ther - 2 weeks
|
modafinil Sensitive: C3 – Early Trials
Cancer Gene Ther - 2 weeks
|
TP53 mutation
|
Ovarian Cancer
|
TP53 mutation
|
Ovarian Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
Cancer Gene Ther - 2 weeks
|
Immunotherapy Sensitive: C3 – Early Trials
Cancer Gene Ther - 2 weeks
|
AR positive
|
Ovarian Cancer
|
AR positive
|
Ovarian Cancer
|
enzalutamide Sensitive: C3 – Early Trials
Gynecol Oncol - 3 weeks
|
enzalutamide Sensitive: C3 – Early Trials
Gynecol Oncol - 3 weeks
|
MUC1 expression
|
Ovarian Cancer
|
MUC1 expression
|
Ovarian Cancer
|
P-MUC1C-ALLO1 Sensitive: D – Preclinical
SITC 2021 - 3 weeks
|
P-MUC1C-ALLO1 Sensitive: D – Preclinical
SITC 2021 - 3 weeks
|
VTCN1 expression
|
Ovarian Cancer
|
VTCN1 expression
|
Ovarian Cancer
|
SGN-B7H4V Sensitive: D – Preclinical
SITC 2021 - 3 weeks
|
SGN-B7H4V Sensitive: D – Preclinical
SITC 2021 - 3 weeks
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
olaparib + bevacizumab Sensitive: A1 - Approval
|
olaparib + bevacizumab Sensitive: A1 - Approval
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
BRCA2 mutation
|
Ovarian Cancer
|
BRCA2 mutation
|
Ovarian Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
olaparib + bevacizumab Sensitive: A1 - Approval
|
olaparib + bevacizumab Sensitive: A1 - Approval
|
BRCA2 mutation
|
Ovarian Cancer
|
BRCA2 mutation
|
Ovarian Cancer
|
olaparib + bevacizumab Sensitive: A1 - Approval
|
olaparib + bevacizumab Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
topotecan Sensitive: A1 - Approval
|
topotecan Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
carboplatin + micellar paclitaxel Sensitive: A1 - Approval
|
carboplatin + micellar paclitaxel Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
BRCA2 mutation
|
Ovarian Cancer
|
BRCA2 mutation
|
Ovarian Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
trabectedin Sensitive: A1 - Approval
|
trabectedin Sensitive: A1 - Approval
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
BRCA2 mutation
|
Ovarian Cancer
|
BRCA2 mutation
|
Ovarian Cancer
|
pamiparib Sensitive: A1 - Approval
|
pamiparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
pamiparib Sensitive: A1 - Approval
|
pamiparib Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
ifosfamide Sensitive: A2 - Guideline
|
ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
leucovorin calcium Sensitive: A2 - Guideline
|
leucovorin calcium Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
oxaliplatin Sensitive: A2 - Guideline
|
oxaliplatin Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
leuprolide acetate Sensitive: A2 - Guideline
|
leuprolide acetate Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
exemestane Sensitive: A2 - Guideline
|
exemestane Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
cyclophosphamide oral Sensitive: A2 - Guideline
|
cyclophosphamide oral Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
pemetrexed Sensitive: A2 - Guideline
|
pemetrexed Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
melphalan Sensitive: A2 - Guideline
|
melphalan Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
irinotecan Sensitive: A2 - Guideline
|
irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
trametinib Sensitive: A2 - Guideline
|
trametinib Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
fulvestrant Sensitive: A2 - Guideline
|
fulvestrant Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
etoposide IV Sensitive: A2 - Guideline
|
etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
sorafenib Sensitive: A2 - Guideline
|
sorafenib Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
tamoxifen Sensitive: A2 - Guideline
|
tamoxifen Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
bevacizumab Resistant: A2 - Guideline
|
bevacizumab Resistant: A2 - Guideline
|
BRCA2 mutation
|
Ovarian Cancer
|
BRCA2 mutation
|
Ovarian Cancer
|
bevacizumab Resistant: A2 - Guideline
|
bevacizumab Resistant: A2 - Guideline
|
MSI-H/dMMR
|
Ovarian Cancer
|
MSI-H/dMMR
|
Ovarian Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
megestrol Sensitive: A2 - Guideline
|
megestrol Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Ovarian Cancer
|
NTRK1 fusion
|
Ovarian Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Ovarian Cancer
|
NTRK1 fusion
|
Ovarian Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Ovarian Cancer
|
NTRK3 fusion
|
Ovarian Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Ovarian Cancer
|
NTRK2 fusion
|
Ovarian Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Ovarian Cancer
|
NTRK3 fusion
|
Ovarian Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Ovarian Cancer
|
NTRK2 fusion
|
Ovarian Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
letrozole Sensitive: A2 - Guideline
|
letrozole Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
anastrozole Sensitive: A2 - Guideline
|
anastrozole Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
pazopanib Sensitive: A2 - Guideline
|
pazopanib Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
carboplatin + ifosfamide Sensitive: A2 - Guideline
|
carboplatin + ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
paclitaxel + ifosfamide Sensitive: A2 - Guideline
|
paclitaxel + ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
CP Sensitive: A2 - Guideline
|
CP Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
EP Sensitive: A2 - Guideline
|
EP Sensitive: A2 - Guideline
|
TMB-H
|
Ovarian Cancer
|
TMB-H
|
Ovarian Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
BEP Sensitive: A2 - Guideline
|
BEP Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
VAC Sensitive: A2 - Guideline
|
VAC Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
cisplatin + ifosfamide Sensitive: A2 - Guideline
|
cisplatin + ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
olaparib + bevacizumab Sensitive: A2 - Guideline
|
olaparib + bevacizumab Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
bevacizumab + niraparib Sensitive: A2 - Guideline
|
bevacizumab + niraparib Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
carboplatin + gemcitabine Sensitive: A2 - Guideline
|
carboplatin + gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
IMGN 853 Sensitive: B - Late Trials
|
IMGN 853 Sensitive: B - Late Trials
|
BRCA2 mutation
|
Ovarian Cancer
|
BRCA2 mutation
|
Ovarian Cancer
|
trabectedin Sensitive: B - Late Trials
|
trabectedin Sensitive: B - Late Trials
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
olaparib + cediranib Sensitive: B - Late Trials
|
olaparib + cediranib Sensitive: B - Late Trials
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
olaparib Sensitive: B - Late Trials
|
olaparib Sensitive: B - Late Trials
|
BRCA2 mutation
|
Ovarian Cancer
|
BRCA2 mutation
|
Ovarian Cancer
|
olaparib + cediranib Sensitive: B - Late Trials
|
olaparib + cediranib Sensitive: B - Late Trials
|
PD-L1 expression
|
Ovarian Cancer
|
PD-L1 expression
|
Ovarian Cancer
|
bevacizumab + atezolizumab Resistant: B - Late Trials
|
bevacizumab + atezolizumab Resistant: B - Late Trials
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
trabectedin Sensitive: B - Late Trials
|
trabectedin Sensitive: B - Late Trials
|
BRCA2 mutation
|
Ovarian Cancer
|
BRCA2 mutation
|
Ovarian Cancer
|
PARP inhibitor Sensitive: B - Late Trials
|
PARP inhibitor Sensitive: B - Late Trials
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
PARP inhibitor Sensitive: B - Late Trials
|
PARP inhibitor Sensitive: B - Late Trials
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
OMP-305B83 Sensitive: B - Late Trials
|
OMP-305B83 Sensitive: B - Late Trials
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
ABT-888 Sensitive: B - Late Trials
|
ABT-888 Sensitive: B - Late Trials
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
fluzoparib Sensitive: B - Late Trials
|
fluzoparib Sensitive: B - Late Trials
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
rucaparib Sensitive: B - Late Trials
|
rucaparib Sensitive: B - Late Trials
|
BRCA2 mutation
|
Ovarian Cancer
|
BRCA2 mutation
|
Ovarian Cancer
|
fluzoparib Sensitive: B - Late Trials
|
fluzoparib Sensitive: B - Late Trials
|
RAD51D mutation
|
Ovarian Cancer
|
RAD51D mutation
|
Ovarian Cancer
|
rucaparib Sensitive: B - Late Trials
|
rucaparib Sensitive: B - Late Trials
|
RAD51C mutation
|
Ovarian Cancer
|
RAD51C mutation
|
Ovarian Cancer
|
rucaparib Sensitive: B - Late Trials
|
rucaparib Sensitive: B - Late Trials
|
HRD
|
Ovarian Cancer
|
HRD
|
Ovarian Cancer
|
ABT-888 Sensitive: B - Late Trials
|
ABT-888 Sensitive: B - Late Trials
|
TTC39B rs7874043
|
Ovarian Cancer
|
TTC39B rs7874043
|
Ovarian Cancer
|
carboplatin + paclitaxel Sensitive: B - Late Trials
|
carboplatin + paclitaxel Sensitive: B - Late Trials
|
TTC39B rs72700653
|
Ovarian Cancer
|
TTC39B rs72700653
|
Ovarian Cancer
|
carboplatin + paclitaxel Sensitive: B - Late Trials
|
carboplatin + paclitaxel Sensitive: B - Late Trials
|
PSIP1 overexpression
|
Ovarian Cancer
|
PSIP1 overexpression
|
Ovarian Cancer
|
carboplatin + paclitaxel Resistant: B - Late Trials
|
carboplatin + paclitaxel Resistant: B - Late Trials
|
